Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease

Abstract

Dementia with Lewy bodies (DLB) and Parkinson's Disease (PD) are common causes of motor and cognitive deficits and are associated with the abnormal accumulation of alpha-synuclein (α-syn). This study investigated whether passive immunization with a novel monoclonal α-syn antibody (9E4) against the C-terminus (CT) of α-syn was able to cross into the CNS and ameliorate the deficits associated with α-syn accumulation. In this study we demonstrate that 9E4 was effective at reducing behavioral deficits in the water maze, moreover, immunization with 9E4 reduced the accumulation of calpain-cleaved α-syn in axons and synapses and the associated neurodegenerative deficits. In vivo studies demonstrated that 9E4 traffics into the CNS, binds to cells that display α-syn accumulation and promotes α-syn clearance via the lysosomal pathway. These results suggest that passive immunization with monoclonal antibodies against the CT of α-syn may be of therapeutic relevance in patients with PD and DLB.

Full text

We don’t show the text of a retracted or withdrawn paper. The record stays, so citations to it can be checked.

Cited by papers we hold 21

• Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction · 2023
  No notice
• Neuroinflammation and Parkinson’s Disease—From Neurodegeneration to Therapeutic Opportunities · 2022
  No notice
• Alpha-Synuclein Aggregation Pathway in Parkinson’s Disease: Current Status and Novel Therapeutic Approaches · 2022
  No notice
• Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications · 2020
  No notice
• Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054 · 2019
  No notice
• Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease · 2019
  No notice
• Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation · 2018
  No notice
• Novel DNA Aptamers for Parkinson’s Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation · 2018
  Not checked
• Linking Neuroinflammation and Neurodegeneration in Parkinson’s Disease · 2018
  No notice
• C-terminal calcium binding of α-synuclein modulates synaptic vesicle interaction · 2018
  No notice
• Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration · 2018
  No notice
• Alpha-synuclein oligomers: a new hope · 2017
  No notice
• Alpha-Synuclein Oligomers—Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders · 2016
  No notice
• First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers · 2016
  No notice
• Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy · 2015
  No notice
• Insights into Neuroinflammation in Parkinson’s Disease: From Biomarkers to Anti-Inflammatory Based Therapies · 2015
  No notice
• Impaired intracellular trafficking defines early Parkinson's disease · 2015
  No notice
• RETRACTED ARTICLE: Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 – implications for dementia with Lewy bodies · 2014
  Not checked
• Protein phosphorylation in neurodegeneration: friend or foe? · 2014
  No notice
• Rodent models of Parkinson's disease: beyond the motor symptomatology · 2013
  No notice

and 1 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.